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Purpose: Acne vulgaris is a skin disorder of the sebaceous follicles, involving 
h  yperkeratinization and perifollicular inflammation. Aberrant extracellular matrix r  emodeling 
due to matrix metalloproteinases (MMPs) has been associated with the presence of acne 
  conditions. Given the complex pathophysiology of acne, novel topical therapies should include 
combination products that target multiple pathogenetic mechanisms. In this pilot study we 
investigated the changes in gene expression of extracellular MMPs, the tissue inhibitors of 
metalloproteinases, and proinflammatory molecules after 45 days of topical application of a 
combination product containing nicotinamide, retinol, and 7-dehydrocholesterol in 16 patients 
with inflammatory acne on their back.
Materials and methods: Skin biopsies were obtained before and after treatment for gene 
expression studies.
Results: Quantitative real-time polymerase chain reaction revealed a significant downregulation 
of MMP-1, MMP-2, MMP-9, MMP-14, interleukin-6, monocyte chemoattractant protein-1, and 
macrophage migration inhibitory factor. In contrast, the tissue inhibitors of metalloproteinases 
and transforming growth factor-β1 were significantly upregulated. The gene expression findings 
correlated well with the clinical treatment response.
Conclusions: The combination of nicotinamide, retinol, and 7-dehydrocholesterol appears to 
be effective for acne treatment from both clinical and molecular standpoints.
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Introduction
Acne vulgaris is a common chronic inflammatory cutaneous disease involving the 
pilosebaceous unit.1–3 Epidemiological estimates suggest that acne can affect up to 
50.9 percent of women and 42.5 percent of men throughout their twenties and may 
continue to occur throughout adulthood.4 Acne is a complex multifactorial condi-
tion with several pathogenic factors. In general, acne is considered to involve excess 
sebum production and hyperplasia of the sebaceous glands, the subsequent formation 
of microcomedones associated with the hyperkeratinization of the follicular wall, and 
the induction of inflammatory reactions in keratinocytes and sebocytes with invaded 
inflammatory cells.5–7 Of note, Propionibacterium acnes (P . acnes) – a Gram-positive 
anaerobic microbial species found in sebum-rich skin – is considered to perpetu-
ate the pathogenetic process of acne through the induction of proinflammatory and 
chemotactic molecules.8,9
Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
33
OriginAl reSeArCH
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/CCID.S29537Clinical, Cosmetic and Investigational Dermatology 2012:5
In recent years, molecular studies have shown a key role 
for aberrant extracellular matrix remodeling in the patho-
genesis of acne. This process is regulated by matrix metal-
loproteinases (MMPs) and their inhibitor enzymes, the tissue 
inhibitors of metalloproteinases (TIMPs).10 In a landmark 
study, Kang et al11 demonstrated that transcription factors 
nuclear factor-kappa B and activator protein-1 are activated 
in acne lesions, ultimately leading to an increased expression 
of inflammatory cytokines and MMPs. In line with these 
  findings, Papakonstantinou et al12 have shown that MMPs and 
TIMPs of epithelial origin are involved in acne pathogenesis, 
and that treatment with isotretinoin reduces the expression 
of MMP-9 and MMP-13 in keratinocytes. Using gene array 
expression profiling, Trivedi et al13 reported that most of the 
genes dysregulated in acne are involved in the inflammation 
and extracellular matrix remodeling pathways. Choi et al14 
have shown that the expression of proMMP-2 is induced by 
P . acnes through the nuclear factor-kappa B pathway.
Most of the conventional therapeutic agents currently 
used in the management of acne are designed to hit a single 
pathophysiological target.15 Unfortunately, the physiological 
and mechanistic deregulations responsible for acne initiation 
and perpetuation implicate a number of genes or signal-
ing cascades so that it appears evident that multitargeted 
approaches are requested to overcome this skin disorder. 
Growing evidence highlights the importance of topical 
combination products targeting multiple pathogenic factors.16 
Due to their complementary and synergistic mechanisms of 
action, combination products hold great promise for a com-
prehensive and multitargeted treatment approach in acne. 
Because nicotinamide,17 retinol,18 and 7-dehydrocholesterol19 
have shown anti-inflammatory and immunomodulatory 
effects at the skin level, in this study we sought to analyze the 
changes in gene expression of extracellular MMPs, TIMPs, 
and proinflammatory molecules after 45 days of application 
of a combination product containing these actives in a topical 
form. The study of gene expression changes in response to a 
topical combination treatment may be useful to gain insights 
into how inflammatory responses and matrix remodeling may 
reflect the observed modifications in skin appearance.
Materials and methods
Study participants
The study population comprised 16 Caucasian patients 
aged .18 years (five men and eleven women; mean age: 
27.7 years ± 5.1 years) with active inflammatory acne on 
their back. Subjects were excluded if they had previously 
received oral antibiotics, benzoyl peroxide, tretinoin, and 
oral retinoids. In addition, patients with endocrine disease, 
diabetes mellitus, or severe physical illnesses or those who 
were currently using oral contraceptives, implantable con-
traceptives, prednisone, or other steroids were not eligible 
for participation. This study has been approved by the 
local ethics committee and conforms to the Declaration of 
  Helsinki. Before the study, each participant was informed 
about the purpose of the study, and signed informed consents 
were obtained.
Materials
Test materials were supplied by Biodue S.p.A. (Tavarnelle 
Val Di Pesa, Italy). The topical preparation tested in this 
study contained nicotinamide (4% weight/weight), retinol 
(1% weight/weight), and 7-dehydrocholesterol (0.5% weight/
weight) in a moisturizer base. The concentrations of the 
actives were fixed based on previous studies.20–22
Procedures
All participants were asked to withdraw any topical product 
14 days before the beginning of the study. In addition, they 
were not allowed to use any topical intervention throughout 
the entire study period. The subjects applied the combina-
tion product twice per day (morning and evening) for a total 
of 45 days. After the baseline visit (Day 0), patients were 
instructed to apply the combination product over the acne 
areas on the back twice per day (once in the morning and 
once in the evening) and were then assessed at follow-up 
visit on Day 45. In line with previous methodology,23 the 
clinical criterion for efficacy was the investigator’s global 
improvement rating on a five-point scale (-1, worsened; 
0, unchanged; 1, improved; 2, markedly improved; and 
3, resolved). Tolerance was assessed by asking patients about 
any signs or symptoms of adverse reactions.
Skin biopsies and gene selection
Paired skin specimens from acne areas were obtained 
on Day 0 and Day 45 through 4 mm punch biopsies for 
  ribonucleic acid (RNA) extraction and molecular analyses. 
Based on the current knowledge of the   pathophysiology of 
acne,1–6 the following genes were selected for the expres-
sion study: MMP-1; MMP-2; MMP-3; MMP-7; MMP-
8; MMP-9; MMP-12; MMP-13; MMP-14; TIMP-1; 
TIMP-2; TIMP-3; transforming growth factor-β (TGF-β); 
  interleukin-6 (IL-6); monocyte chemoattractant protein-1 
(MCP-1); macrophage migration inhibitory factor (MIF); 
and regulated upon activation, normally T-cell expressed, 
and presumably secreted (RANTES).
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Quantitative real-time polymerase  
chain reaction
RNA from baseline and post-treatment skin samples was 
isolated using the RNeasy Mini Kit (Qiagen, Valencia, 
CA) according to the manufacturer’s instructions. Integrity 
of RNA was assessed with agarose gel electrophoresis, 
and RNA quantity was measured by spectrophotometry. 
A 1 µg amount of RNA was reverse transcribed using 
the iScript cDNA Synthesis Kit (BioRad, Hercules, CA) 
according to the manufacturer’s instructions. cDNA was 
stored at -20°C. All quantitative real-time polymerase 
chain reactions   (qRT-PCR) were carried out on a BioRad 
iQ5 Cycler (BioRad). In brief, a 25 µL reaction solution 
consisted of iQ SYBR Green Supermix (BioRad), forward 
and reverse primers (final concentration 400 nM each), and 
cDNA   mixture (40 ng). The conditions for qRT-PCR were 
as follows: preheating at 95°C for 10 minutes, followed by 
40 cycles of 95°C for 10 seconds, 60°C for 15 seconds, and 
72°C for 30 seconds. Melting curves were analyzed for each 
reaction by steadily increasing the temperature from 60°C 
to 95°C.   Fluorescence data were analyzed using the Bio-
Rad iQ5   Optical System Software Version 2.0. To control 
for variations in RNA   quality and quantity, the expression 
of the gene of interest was normalized to the expression 
of hypoxanthine phosphoribosyltransferase-1 (HPRT1 ) 
as a housekeeping gene. mRNA expression levels were 
calculated according to the following formula: 2-∆CT, where 
∆CT (sample) was defined as CT (gene of interest) – CT 
(HPRT1 ). Nucleotide sequences of primers used for qRT-
PCR reactions are available upon request.
Statistical analysis
All calculations were performed using SPSS 17.0 software 
(SPSS, Inc, Chicago, IL). Pre- and post-treatment gene 
expression data were analyzed using paired t-tests after 
adjustment for age and sex. A two-tailed P-value ,0.05 was 
considered statistically significant.
Results
In this study a total of 16 paired skin samples from acne 
areas on the back were obtained before and after 45 days 
of application of a topical combination product and then 
subjected to gene expression studies. Assessment of efficacy 
by the investigators showed that 94% of the patients had 
improved after 45 days of treatments, while 6% demonstrated 
an unchanged state (Table 1). No patient discontinued treat-
ment due to adverse effects.
Table 1 Physician’s overall ratings for the response of inflammatory 
acne after 45 days of topical application of a combination product 
containing nicotinamide, retinol, and 7-dehydrocholesterol in 16 
patients with inflammatory acne on their back
Rating Number (%)
Worsened 0 (0%)
Unchanged 1 (6%)
Improved 10 (63%)
Markedly improved 4 (25%)
Resolved 1 (6%)
Total 16 (100%)
In order to reveal potential treatment-related changes 
in gene expression in areas with acne lesions, qRT-PCR-
based expression analyses of 17 genes were performed. 
All   examined genes were selected due to their potential 
relevance in inflammation and matrix remodeling under 
acne   conditions. Expression analysis was successful in all 
skin biopsies. qRT-PCR data concerning MMPs and TIMPs 
(Table 2) revealed a significant downregulation of MMP-1, 
MMP-2, MMP-9, and MMP-14 after 45 days of treatment 
compared with baseline values. In addition, TIMPs and 
TGF-β were significantly upregulated by the topical combi-
nation treatment. The expression of other MMPs and TIMPs 
genes was unchanged (data not shown).
Table 3 shows the changes in inflammatory gene 
  expression. The results indicated that IL-6, MCP-1, and 
MIF were significantly downregulated by topical treatment, 
whereas no significant changes in the expression of  RANTES  
were detected.
Table 2   Relative  gene  expression  values  (MMPs  and  their 
inhibitors) before and after 45 days of topical application of a 
combination  product  containing  nicotinamide,  retinol,  and 
7-dehydrocholesterol in 16 patients with inflammatory acne on 
their back
Baseline 45 days P 
MMP-1 338 ± 77 211 ± 41 ,0.001
MMP-2 728 ± 184 461 ± 191 ,0.001
MMP-9 1.4 ± 0.3 0.6 ± 0.2 ,0.001
MMP-14 378 ± 91 256 ± 53 ,0.001
TGF-β 88 ± 11 146 ± 26 ,0.001
TIMP-1 2918 ± 846 6483 ± 1091 ,0.001
TIMP-2 212 ± 67 501 ± 117 ,0.001
TIMP-3 381 ± 118 663 ± 193 ,0.001
Notes: Messenger ribonucleic acid expression levels were calculated according to 
the formula 2-∆CT, where ∆CT (sample) was defined as CT (gene of interest) – CT 
(HPrT1). Only significant values after adjustment for age and sex are shown.
Abbreviations: MMP, matrix metalloproteinase; TgF, transforming growth factor; 
TiMP, tissue inhibitor of metalloproteinases.
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Discussion
The results of this study support the safety and efficacy of a 
combination product containing nicotinamide, retinol, and 
7-dehydrocholesterol in the treatment of acne. More impor-
tantly, we have shown by molecular analysis that the topical 
application of this combination resulted in a significant 
downregulation of  MMP-1, MMP-2, MMP-9, MMP-14, IL-6, 
MCP-1, and MIF in acne areas. In contrast, both TIMPs and 
TGF-β were significantly upregulated.
Topical application of nicotinamide has a stabilizing 
effect on epidermal barrier function, as reflected by a reduc-
tion in transepidermal water loss and by an improvement in 
the moisture content of the horny layer.24 Retinol (preformed 
vitamin A) plays a crucial role in cell growth and differ-
entiation of human epithelial tissues.25 The combined use 
of nicotinamide, retinol, and 7-dehydrocholesterol in acne 
has not been previously studied either clinically or at the 
molecular level. 7-dehydrocholesterol is the main precursor 
of vitamin D – a key modulator of keratinocyte differentiation 
and proliferation – in the skin.19 In addition, specific vitamin 
D derivatives may exhibit comedolytic activity.26 The results 
of our molecular analyses indicate that the combination of 
nicotinamide, retinol, and 7-dehydrocholesterol significantly 
decreased MMP expression and increased TIMP expression. 
In addition, we have also demonstrated a significant upregula-
tion of  TGF-β, a master regulator of the expression of MMPs 
and extracellular matrix remodeling.27 An imbalance in the 
ratio of MMPs to TIMPs has been suggested to play a key 
role in the development of atrophic or hypertrophic scars in 
patients with acne.28 As prevention is the main step in avoiding 
the appearance of postacne scars,28 our gene expression data 
seem to suggest that a combined treatment approach may have 
value in preventing the disfiguring consequences of acne.
Inflammation is involved in acne conditions by recruiting 
leukocytes and promoting extracellular matrix remodeling.3 
We found that the expression of three inflammatory genes 
(IL-6, MCP-1, and MIF ) was significantly downregulated 
in areas with acne by topical treatment. IL-6 is a cytokine 
with multiple and complex proinflammatory effects and is 
produced primarily by macrophages, T cells, endothelial cells, 
and fibroblasts.29 The major biological effects of IL-6 also 
include stimulation of the proliferation and differentiation of 
T lymphocytes and regulation of the acute-phase response.29 
IL-6 can play a role as a regulator of extracellular matrix 
deposition and is involved in the immune response to P . acnes; 
as a consequence, it may be an important determinant of 
acne.30 MCP-1 is a chemokine responsible for the recruit-
ment of monocytes to sites of inflammation and is related to 
the extent of macrophage infiltration into the skin.31 MIF is 
an integral component of the host antimicrobial alarm sys-
tem and stress response that promotes the proinflammatory 
functions of immune cells.32 Taken together, these results 
demonstrate that the combination of nicotinamide, retinol, and 
7-dehydrocholesterol may be useful not only to prevent matrix 
remodeling but also to inhibit the inflammatory reactions that 
are paramount in the clinical manifestations of acne.
There are several limitations of this study that need to be 
mentioned. First, we performed gene expression studies in 
acne areas of the back. Therefore, caution is needed in the 
extrapolation of our findings to other skin areas. Second, this 
study was conducted in Caucasian individuals, so results 
cannot be simply extrapolated to populations with different 
ethnic backgrounds. Third, our study should be considered 
an exploratory analysis, and further data on protein levels 
are needed to extend and confirm our results. Although we 
showed that a combination treatment is effective in modulat-
ing the main molecular alterations associated with acne, our 
study did not compare the effect of the combination product 
with that of each compound alone (i.e., nicotinamide, retinol, 
and 7-dehydrocholesterol alone). Our study was not designed 
as a comparative trial of different treatment strategies. Acne 
patients should most likely be treated on an individual basis 
according to each patient’s disease characteristics, based on 
clinical trial data and influenced by the personal experience 
of the physician. In the future, prospective evaluation of com-
bination versus simple or sequential single-agent therapy may 
help identify optimal treatment approaches. Another limita-
tion that should be kept in mind is that the regulation of gene 
expression does not invariably correlate with protein expres-
sion levels, because molecular mechanisms of   transcriptional 
pathways differ from those of translation ones. Future studies 
using immunohistochemical staining and/or Western blotting 
are needed to corroborate our findings. Finally, the lack of a 
control arm makes our data exploratory in nature.
Table 3 relative gene expression values (inflammatory genes) 
before and after 45 days of topical application of a combination   
product containing nicotinamide, retinol, and 7-dehydro-cholesterol 
in 16 patients with inflammatory acne on their back
Baseline 45 days P
IL-6 1775 ± 867 944 ± 569 ,0.001
MCP-1 544 ± 181 225 ± 86 ,0.001
MIF 358 ± 117 265 ± 98 ,0.01
Notes: Messenger ribonucleic acid expression levels were calculated according to 
the formula 2-∆CT, where ∆CT (sample) was defined as CT (gene of interest) – CT 
(HPrT1). Only significant values after adjustment for age and sex are shown.
Abbreviations: MCP, monocyte chemoattractant protein; MIF, migration inhibitory 
factor; il-6, interleukin-6.
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Conclusions
Notwithstanding the pilot nature of the study, our data 
support at the molecular level the safety and efficacy of a 
combination product containing nicotinamide, retinol, and 
7-dehydrocholesterol in the treatment of acne. This approach 
seems to be effective in restoring the unbalanced extracellular 
matrix remodeling and the inflammatory component, which 
are paramount to the pathogenesis of acne.
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